Jianxin Medical Secures Tens of Millions in Series A+ Funding to Advance Original Chinese Minimally Invasive Surgical Solutions

VCBeat has learned that Qingdao Jianxin Medical Technology Co., Ltd. (hereinafter referred to as “Jianxin Medical”) recently completed an A+ round of financing amounting to tens of millions of yuan. This round was jointly invested by Qingdao Venture Capital and Huatong Venture Capital, with Qingchuang Huiyi serving as the exclusive financial advisor. The funds will be used to accelerate Jianxin Medical’s development of an integrated minimally invasive surgical diagnosis and treatment system, achieve a closed loop for clinical applications in the field of minimally invasive surgery, and enable China’s medical device industry to “overtake on the straightaway” through original Chinese innovations.

Jianxin Medical's Minimally Invasive Surgical Treatment Equipment:The world’s first intelligent dual-engine dynamic hybrid energy surgical system, designed for diverse clinical scenarios, has successfully been approved under the Ministry of Science and Technology’s Key R&D Program and entered the NMPA’s priority review channel, with NMPA registration and market launch expected by mid-2024. The first anti-adhesion ultrasonic energy system for 5mm vessel cutting and hemostasis has obtained the NMPA Class III medical device registration certificate, has been applied in multiple domestic surgical robots, and its technology has been licensed by internationally renowned companies. The world’s first dual-frequency ultrasonic lithotripsy system for ureteral stones without thermal injury has completed prototype development and is about to enter regulatory testing.

Jianxin Medical's Minimally Invasive Surgical Visualization System:The world’s first fully original, dual-probe 3D ultrasound system, which simultaneously addresses “temporal precision” and “positional accuracy,” has completed its prototype and is about to undergo registration testing. By providing physicians with “two” fluoroscopic eyes, this product effectively resolves the limitation of conventional ultrasound imaging, which offers only two-dimensional images and cannot perform real-time, precise localization of lesions within a three-dimensional spatial coordinate system.

By developing a series of therapeutic devices and building a visualized surgical platform, Jianxin Medical has established a complete closed-loop clinical application system for integrated minimally invasive surgical diagnosis and treatment, enabling clinicians to monitor surgical outcomes in real time and gain comprehensive oversight of the surgical process during operations.

Regarding this round of financing,Feng Qingyu, Founder of Jianxin MedicalIt was stated that this financing will provide strong momentum for Qingdao Jianxin Medical Technology Co., Ltd. The company will remain committed to driving clinical transformation through innovation, conducting product R&D oriented toward addressing clinical pain points, and continuously advancing domestically produced medical equipment toward high-end and intelligent development. In the fields of minimally invasive surgical treatment devices and visualized surgical platforms, the company has filed over 80 patent applications, with invention patents accounting for 40%, and has won awards in provincial and ministerial-level medical device innovation competitions on multiple occasions.

Qingdao Jianxin Medical Technology Co., Ltd. has also joined forces with the China Technology Exchange, the Liaoning Provincial Institute for Medical Device Inspection and Testing under the National Medical Products Administration, Qingdao Innovation Investment Co., Ltd., and Kunshan Kesin Technology Co., Ltd. to establish an Innovation Research Institute. This institute facilitates industrial development and product innovation through coordinated efforts across key value chains, including intellectual property commercialization, product technology development, professional technical services, full-lifecycle product incubation, and investment and financing services.

In the future, the company will continue to be grounded in source innovation, constantly improve the system for translating innovative achievements into practical applications, and truly lead the development of minimally invasive surgical equipment with its fully original minimally invasive surgical products and powerful core underlying technologies, thereby fulfilling the goal and mission of “achieving overtaking on a straight track in the medical device industry through original Chinese innovations.”

Wei Meng, Deputy General Manager of Qingdao Venture CapitalStatement: Jianxin Medical is one of the few companies in the field of minimally invasive surgery with R&D capabilities across a full energy platform encompassing acoustics, optics, and electrosurgery. Its core team boasts over 20 years of R&D experience in these specialized segments. The company’s flagship products are built on fully independently developed technology platforms, resulting in superior product quality, higher reliability, greater flexibility in iteration, and lower costs. Multiple independently developed products by Jianxin Medical hold significant advantages in the field of minimally invasive surgery, offering surgeons improved procedural techniques that further enhance surgical precision, reduce the risk of complications, and shorten operative time. Through this round of capital increase, we are honored to have the opportunity to establish a deep strategic partnership with Jianxin Medical. We are highly optimistic about Jianxin’s future market development and look forward to the timely commercialization of its various products currently under development.

Head of Huatong Venture CapitalStatement: We are delighted to participate in this round of financing for Jianxin Medical. Jianxin Medical has established a comprehensive layout in the field of minimally invasive surgery, and its integrated diagnosis and treatment corporate positioning aligns well with the development direction of China’s medical device industry. The company demonstrates significant advantages in R&D, clinical applications, commercialization, and supply chain management, while its team possesses extensive experience and resources in the medical device sector. Against the backdrop of centralized procurement, independent innovation capability serves as the cornerstone for success in the medical device industry. Coupled with Jianxin Medical’s platform-based strategic layout, we believe the company is poised to become a benchmark among domestic medical device enterprises in China.

Cheng Xiangkuan, Minister of the Financial Investment Department at Qingchuang HuiyiStatement: It is a great honor to serve as the exclusive financial advisor for Jianxin Medical’s current round of financing. We highly recognize Jianxin Medical’s strong capabilities in product R&D and clinical certification. The company’s rich product pipeline covers multiple clinical departments, and its diversified commercialization strategy efficiently drives overall revenue. We believe that medical device companies with original Chinese innovation strength, such as Jianxin Medical, will become leading enterprises in China’s surgical field in the future.

Jianxin Medical is a medical device company specializing in the integration of minimally invasive surgical diagnosis and treatment. The company boasts a professional R&D team with multidisciplinary expertise spanning acoustics, optics, electronics, and mechanics, and possesses original technologies across energy, imaging, and non-invasive disciplines. Jianxin Medical has established a comprehensive system for translating innovative achievements into practical applications, building R&D platforms for real-time imaging technology, acoustic-electrical energy technology, ultrasound therapy technology, and materials and process technology. The company strategically focuses on ultrasound energy surgery and ultrasound-guided interventional imaging.

Honors Received by Jianxin Medical: Second Prize in the Medical and Health Special Category of the 2nd “Bloom Cup” 5G Application Collection Competition; First Prize in the 2021 China Overseas Talent Innovation and Entrepreneurship Project Competition; First Prize in the 5th (2022) China Medical Device Innovation and Entrepreneurship Competition; Third Prize in the 2022 China International Elite Entrepreneurship and Innovation Competition; First Prize in the Medical Device Professional Category of the 2022 Lanbei International Innovation and Entrepreneurship Competition; Named one of the “Top 10 Capital-Favored Enterprises in Qingdao 2023”; Swept two First Prizes in the 6th (2023) China Medical Device Innovation and Entrepreneurship Competition.

Qingdao Innovation Venture Capital Co., Ltd. (hereinafter referred to as “Qingdao Venture Capital,” formerly known as the Qingdao Municipal Venture Capital Guidance Fund Management Center) was established in September 2021. It is a subsidiary of Qingdao Caitong Group, with a registered capital of RMB 3 billion. The company serves as the entrusted manager of the Qingdao Municipal Government Guidance Fund and is primarily engaged in market-oriented investment and fund management activities, including government guidance fund management, private equity investment, and investment consulting.

Qingdao Venture Capital is committed to co-building a lasting foundation with investment institutions and innovative enterprises, striving to become a premier ecosystem platform that leads the allocation of resource factors and empowers the real economy. By the end of 2022, it had participated in over 90 funds, with a total capital scale exceeding RMB 110 billion. Focusing on key industrial directions at the national, provincial, and municipal levels, it has made equity investments in more than 800 companies through its fund participations, facilitating the listing of over 70 portfolio companies, including Qingdao Gaoce, Degute, and Haitai Xin Guang, on multi-tiered capital markets. Fully leveraging the role of government guidance funds in "attracting both talent and investment," it has successfully facilitated the relocation of more than 80 non-local enterprises to Qingdao. Actively expanding its direct investment business segment, it established Qingdao Caitong Venture Capital Management Co., Ltd. to invest in high-potential enterprises across various sub-sectors of strategic emerging industries. In 2021, it pioneered a new model nationwide that leverages fiscal funds by converting grants into equity investments to empower talent development.

Huaton Venture Capital is actively committed to building a new investment landscape characterized by government fund guidance, private capital participation, efficient market operations, industrial synergy, and sound organizational structures. In recent years, Huaton Venture Capital has partnered with leading industry institutions to create a “parent-subsidiary fund cluster” covering areas such as funds of funds (FOFs), sub-funds focused on emerging industries, and stable income-oriented funds. This initiative has effectively promoted the close integration of industry and capital, as well as high-quality development, earning Huaton Venture Capital the title of “Top 10 Active Venture Capital Institutions in Qingdao” for consecutive years. To date, funds under Huaton Venture Capital hold nearly 50 investment projects, with a total investment amount of approximately RMB 3 billion. By focusing on the key industrial ecosystem of Qingdao City and investing in leading enterprises within niche segments of emerging industry tracks, Huaton Venture Capital has secured high-quality industrial resources, thereby supporting the strengthening, supplementation, and extension of Qingdao’s industrial chains.

Qingchuang Huiyi (Qingdao) Technology Co., Ltd. (hereinafter referred to as "Qingchuang Huiyi") was jointly established by Qingdao Innovation Investment Development Co., Ltd. and Shanghai Bofang Medical Technology Co., Ltd. Based on precise industry data and grounded in professional technical guidance, the company is building a digital full-industry-chain empowerment and innovation incubation platform to promote the digital transformation of the medical device industry.

Leveraging its professional technical service team and robust capital empowerment system, the company focuses on building a “One Body, Two Wings” operational model. By establishing one platform (Industrial Service Platform) and two centers (Industrial Technology Center and Academic Education Center), it provides comprehensive, one-stop professional services for medical device innovation—covering resource coordination to technical support, R&D and design to production and operations, and seed/angel investment to corporate IPO—thereby forming a closed-loop ecosystem for the entire industry and fully promoting product innovation and high-quality industrial development.